At a glance · for buyers and watchdogs
CELIX PHARMA LTd has won £80.2m across 5 public-sector buyers, with 16 live contracts. No active Companies House risk flags.
Why: top buyer NHS England at 78% · 0 active risk flags · 0 modifications.
ESG & policies vault · 0/5
Key governance & sustainability policies. Published documents link out; missing ones are greyed.
Capabilities
What this supplier does, where they sit, who they sell to.
- NHS National Pharmaceuticals Transition 2022_1
Extracted automatically from celixpharma.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.
Case studies
Delivery stories the supplier has published, with sector and outcome.
No case studies yet
Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.
Buyer references
Named public-sector contacts who have agreed to act as a reference.
No buyer references yet
Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.
Accreditations & memberships
Independently issued. Verification dates cross-checked against issuer registers.
No accreditations recorded
B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.
KPI performance
Delivery, budget and satisfaction scores reported quarterly by buyers.
No verified KPI scores yet
Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.
Contracts · 16 live · 8 historic
Pulled from Contracts Finder & Find a Tender. Most recent first.
| Title | Buyer | CPV | Awarded | Value | Term | Status |
|---|---|---|---|---|---|---|
| NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) | — | 01 Jul 2026 | £16.8m | 2 yrs | pending | |
| NHS England | — | 01 May 2026 | £14.8m | 17 mo | pending | |
| NHS England | — | 01 Jun 2026 | £17.7m | 12 mo | pending | |
| NHS England | — | 01 Feb 2026 | £25.9m | 1.7 yrs | pending | |
| NHS England | 33600000 | 01 Oct 2024 | £1.4m | 1.7 yrs | Closed | |
| NHS England | 33600000 | 01 May 2024 | £630k | 17 mo | Closed | |
| NHS England | 33600000 | 01 Feb 2023 | £2.1m | 2 yrs | Closed | |
| NHS England and NHS Improvement | 33600000 | 29 Jul 2022 | £944k | 1.8 yrs | Closed | |
| NHS England | — | — | — | — | Live | |
| Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts) | — | — | — | — | Live |
Top buyers · 5 buyers · top 3 = 100%
Share of awarded value. Concentration fires above 40% for any single buyer.
Geography
Distribution of awarded value by buyer region.
Peers
Suppliers with overlapping CPVs & buyers (last 24m). CELIX PHARMA LTd highlighted.
| Supplier | SME? | Awarded · 24m | Contracts |
|---|---|---|---|
| Yes | £121.0m | 22 | |
| Yes | £117.6m | 18 | |
| Yes | £95.2m | 12 | |
CP CELIX PHARMA LTd | No | £75.2m | — |
| Yes | £72.5m | 12 | |
| Yes | £71.2m | 21 |
Red flags · 0 active
Automated scan of Companies House status, charges and insolvency records.
Compliance scorecard
Derived from Companies House filings — not a full supplier-assurance check.
Modifications
Variations to awarded contracts logged under Procurement Act 2023 s.74.
No modifications recorded
No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.
News mentions
UK trade press & nationals, matched to this supplier.
No news mentions found
We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.
Companies House
Live sync — registered details, directors, PSC and SIC codes.
Registered details
- Company no.
- 12474195
- Status
- Active
- Type
- Private limited
- Incorporated
- 20 Feb 2020
- Reg. office
- 12 Constance Street, International House, London, E16 2DQ
- SIC codes
- 21200 · 46460
- Last accounts
- 31 Mar 2025
- Next accounts due
- 31 Dec 2026
Directors & PSC
- VASUDEVAN, Subramanian Vishar, Mr. — directorAppointed 12 Oct 2020
- KOHLI, Subir, Mr. — directorAppointed 01 Jun 2020
- SOOGAREDDY, Shantreddy Channareddy, Mr. — directorAppointed 01 Jun 2020
- Mr. Subir Kohli — person with significant controlownership of shares 50 to 75 percent · voting rights 50 to 75 percent · right to appoint and remove directors
- Mr. Shantreddy Channareddy Soogareddy — person with significant controlownership of shares 25 to 50 percent · voting rights 25 to 50 percent
Financial
Filed accounts from Companies House.
No financial filings on record
Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.
Org tree
Group structure and ownership.
Independent. No parent company or subsidiaries recorded at Companies House for this entity.
Social value · 1/5
Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.
Extracted automatically from celixpharma.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.